D3 Bio, a Chinese drug developer that studies and specifically targets areas where existing approaches to care are not delivering satisfactory outcomes, has raised $200 million in Series A funding.
The round featured Boyu Capital, Matrix Partners China, Sequoia Capital China, Temasek Holdings, and the corporate venture fund of local pharmaceutical services outsourcing player WuXi AppTec. According...
Swapping a traditional fund for a less familiar corporate vehicle represented a gamble for Equis, but the Asian infrastructure manager was confident its approach would make sense to a subset of investors
Taiwan’s technology sector must play an awkward balancing game amid US-China tensions. This could be a surprisingly favorable position for opportunistic investment and global diversifications
Chinese eye disease specialist Elumninex Biosciences has raised a $50 million Series A round led by GL Ventures, Lilly Asia Ventures (LAV), and Quan Capital.
Anacacia Capital has acquired a controlling stake in Pump Haircare, an Australian organic hair products brand that is looking to further expand its online distribution channels.